Vera Therapeutics is trading 10.26% up now at $35.03 as biotechnology stocks rally broadly, with XBI up 2.55% and the Nasdaq Composite up 1.41%.

  • The move appears to be a rebound after the September 16 decline, rather than a fresh company-specific announcement on September 17.
  • Vera’s latest major catalyst was positive September 15 ORIGIN 3 data for TRUTAKNA, including plans for a full FDA filing in Q4 2026.